Alemtuzumab for Multiples Sclerosis: Who and When to treat?Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Monoclonal Antibody Therapies and Neurologic DisordersArch Neurol 65:1162-1165, Novack,J.C.,et al., 2008